Filtered By:
Source: Neurology
Drug: Coumadin

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 64 results found since Jan 2013.

Long-term survival after ischemic stroke in patients with atrial fibrillation
Conclusions: Ischemic stroke approximately triples the mortality rate in patients with atrial fibrillation. This effect persists well beyond the immediate period poststroke and is strongly associated with disability after stroke. Stroke prevention by anticoagulation has even greater beneficial effects on survival than usually considered when focusing solely on 30-day mortality rates.
Source: Neurology - March 24, 2014 Category: Neurology Authors: Fang, M. C., Go, A. S., Chang, Y., Borowsky, L. H., Pomernacki, N. K., Udaltsova, N., Singer, D. E. Tags: Outcome research, Stroke prevention, Cardiac, Cohort studies, Infarction ARTICLE Source Type: research

Summary of evidence-based guideline update: Prevention of stroke in nonvalvular atrial fibrillation: Report of the Guideline Development Subcommittee of the American Academy of Neurology
Objective: To update the 1998 American Academy of Neurology practice parameter on stroke prevention in nonvalvular atrial fibrillation (NVAF). How often do various technologies identify previously undetected NVAF? Which therapies reduce ischemic stroke risk with the least risk of hemorrhage, including intracranial hemorrhage? The complete guideline on which this summary is based is available as an online data supplement to this article. Methods: Systematic literature review; modified Delphi process recommendation formulation. Major conclusions: In patients with recent cryptogenic stroke, cardiac rhythm monitoring probabl...
Source: Neurology - February 24, 2014 Category: Neurology Authors: Culebras, A., Messe, S. R., Chaturvedi, S., Kase, C. S., Gronseth, G. Tags: All Cerebrovascular disease/Stroke SPECIAL ARTICLE Source Type: research

Pre-hospital imaging and thrombolysis in acute stroke in an urban US setting: results of the Cleveland Pre-Hospital Acute Stroke Treatment (PHAST) study group. (S21.002)
CONCLUSIONS: Close to a fifth of patients received acute stroke treatment on MSTU. These findings demonstrate the successful reduction in time to diagnosis and treatment of acute stroke patients using a MSTU. Study Supported by:Disclosure: Dr. Briggs has nothing to disclose. Dr. Taqui has nothing to disclose. Dr. Cerejo has nothing to disclose. Dr. Itrat has nothing to disclose. Dr. Donohue has nothing to disclose. Dr. Organek has nothing to disclose. Dr. Buletko has nothing to disclose. Dr. Sheikhi has nothing to disclose. Dr. Buttrick has nothing to disclose. Dr. Khawaja has nothing to disclose. Dr. Wisco has nothing to ...
Source: Neurology - April 8, 2015 Category: Neurology Authors: Briggs, F., Taqui, A., Cerejo, R., Itrat, A., Donohue, M., Organek, N., Buletko, A., Sheikhi, L., Buttrick, M., Khawaja, Z., Wisco, D., Winners, S., Reimer, A., Frontera, J., Manno, E., Hustey, F., Kralovic, D., Peter, R., Hussain, M., Uchino, K. Tags: Cerebrovascular Disease and Interventional Neurology: Prehospital and Acute Ischemic Stroke Treatment Source Type: research

Risk of ischemic stroke during periods of warfarin discontinuation for surgical procedures: A longitudinal study of 4060 patients with atrial fibrillation (P1.058)
CONCLUSIONS: The risk associated with discontinuation of warfarin for procedures must be recognized and considered in the risk benefit analysis of any procedure.Disclosure: Dr. Jahangir has nothing to disclose. Dr. Malik has nothing to disclose. Dr. Suri has nothing to disclose. Dr. Qureshi has nothing to disclose.
Source: Neurology - April 8, 2015 Category: Neurology Authors: Jahangir, N., Malik, A., Suri, M., Qureshi, A. Tags: Cerebrovascular Disease and Interventional Neurology: Atrial Fibrillation and Cardio-embolic Stroke Source Type: research

Recurrent stroke predictors differ in medically treated patients with pathogenic vs other PFOs
Conclusion: Predictors of recurrence differ when PFO relatedness is classified by the RoPE score, suggesting that patients with CS and PFO form a heterogeneous group with different stroke mechanisms. Echocardiographic features were only associated with recurrence in the high RoPE score group.
Source: Neurology - July 14, 2014 Category: Neurology Authors: Thaler, D. E., Ruthazer, R., Weimar, C., Mas, J.-L., Serena, J., Di Angelantonio, E., Papetti, F., Homma, S., Mattle, H. P., Nedeltchev, K., Mono, M.-L., Jaigobin, C., Michel, P., Elkind, M. S. V., Di Tullio, M. R., Lutz, J. S., Griffith, J., Kent, D. M. Tags: Stroke prevention, All Cerebrovascular disease/Stroke, Risk factors in epidemiology ARTICLE Source Type: research

Potential new uses of non-vitamin K antagonist oral anticoagulants to treat and prevent stroke
Conclusion: There may be a role for NOACs in stroke prevention and treatment beyond atrial fibrillation. Randomized controlled trials are needed to compare NOACs to current stroke prevention and treatment strategies in certain subgroups of patients with cerebrovascular disease.
Source: Neurology - September 21, 2015 Category: Neurology Authors: Yaghi, S., Kamel, H., Elkind, M. S. V. Tags: Stroke prevention, All Cerebrovascular disease/Stroke, Infarction, Cerebral venous thrombosis VIEWS & amp;amp; REVIEWS Source Type: research

Effectiveness and Safety of Apixaban and Rivaroxaban Versus Warfarin for the Secondary Prevention of Stroke or Systemic Embolism Among Nonvalvular Atrial Fibrillation Patients (S51.001)
Conclusions:Among NVAF patients with a prior history of SSE, rivaroxaban reduced ischemic stroke and ICH risk versus warfarin and did not significantly impact major bleeding. Apixaban did not significantly alter patients’ risk of SSE or major bleeding compared to warfarin in this high-risk population.Study Supported by: Bayer Pharma AGDisclosure: Dr. Coleman has received personal compensation for activities with Janssen Scientific affairs, LLC, Bayer Pharma AG, and BIPI . Dr. Coleman has received research support from Janssen Scientific Affairs, LLC, and Bayer Pharma AG. Dr. Bunz has nothing to disclose.
Source: Neurology - April 17, 2017 Category: Neurology Authors: Coleman, C., Bunz, T. Tags: Cerebrovascular Disease and Interventional Neurology: Stroke Prevention and Translation Source Type: research

The Speed and Reliability of Pre-Hospital Point-of-Care Laboratory Testing on the Mobile Stroke Treatment Unit (P4.314)
Conclusion: Critical laboratory tests can be performed rapidly and successfully in a MSTU to assist in early pre-hospital ischemic stroke thrombolysis or warfarin reversal in ICH.Disclosure: Dr. Organek has nothing to disclose. Dr. Taqui has nothing to disclose. Dr. Cerejo has nothing to disclose. Dr. Itrat has nothing to disclose. Dr. Buletko has nothing to disclose. Dr. Cho has nothing to disclose. Dr. Sheikhi has nothing to disclose. Dr. Winners has nothing to disclose. Dr. Rasmussen has nothing to disclose. Dr. Hussain has nothing to disclose. Dr. Uchino has nothing to disclose.
Source: Neurology - April 8, 2015 Category: Neurology Authors: Organek, N., Taqui, A., Cerejo, R., Itrat, A., Buletko, A., Cho, S., Sheikhi, L., Winners, S., Rasmussen, P., Hussain, M., Uchino, K. Tags: Cerebrovascular Disease and Interventional Neurology: Acute Stroke, Prehospital, and Telemedicine Source Type: research

A rare cause of stroke in young: PHACE syndrome (P1.253)
Conclusions:Neurocutaneous syndromes are typically diagnosed in childhood and can be a rare cause of stroke in young. Our patient suffered an ischemic stroke secondary to sequelae of undiagnosed PHACE syndrome. Early identification of neurocutaneous syndromes allows for proper surveillance, evaluation, and preventative education for development of complications.Disclosure: Dr. Fitzgerald has nothing to disclose. Dr. Chandra has nothing to disclose. Dr. Dannenbaum has nothing to disclose. Dr. Sharrief has nothing to disclose.
Source: Neurology - April 17, 2017 Category: Neurology Authors: Fitzgerald, K., Chandra, S., Dannenbaum, M., Sharrief, A. Tags: Genetic Stroke Syndromes, Biomarkers, and Translational/Basic Research Source Type: research

90 Day Outcomes in Stroke/Transient Ischemic Attack Patients Receiving Initial or Follow-up Care in a Comprehensive Outpatient Stroke Center (P3.120)
CONCLUSIONS: The completion of diagnostic evaluation and implementation or adjustment of treatments including optimizing antiplatelet therapy or changing to coumadin when cardiac monitoring demonstrates atrial fibrillation in a timely manner has resulted in better than expected outcomes. We feel this is due to "closing the loop" in the episode of care.Disclosure: Dr. Bates has nothing to disclose. Dr. Westphal has nothing to disclose. Dr. Rainka has nothing to disclose. Dr. Gengo has nothing to disclose.
Source: Neurology - April 9, 2014 Category: Neurology Authors: Bates, V., Westphal, E., Rainka, M., Gengo, F. Tags: Cerebrovascular Disease and Interventional Neurology: Primary and Comprehensive Stroke Centers Source Type: research

Temporary Discontinuation Of Warfarin For Endovascular Procedures And Risk Of Ischemic Stroke (P4.301)
Conclusions: The risk of ischemic stroke during discontinuation of warfarin is higher than expected and requires a careful evaluation of risk and benefits.Disclosure: Dr. Malik has nothing to disclose. Dr. Qureshi has nothing to disclose. Dr. Zeb has nothing to disclose. Dr. Defillo has nothing to disclose. Dr. Thompson has nothing to disclose. Dr. Suri has nothing to disclose. Dr. Qureshi has nothing to disclose.
Source: Neurology - April 8, 2015 Category: Neurology Authors: Malik, A., Qureshi, M., Zeb, H., Defillo, A., Thompson, M., Suri, M., Qureshi, A. Tags: Cerebrovascular Disease and Interventional Neurology: Acute Interventional Treatment for Ischemic Stroke Source Type: research

Vitreous Hemorrhage as a Complication of IV-tPA Therapy in a Patient with Acute Stroke (P4.227)
CONCLUSIONS: To our knowledge, this is the first case report of vitreous hemorrhage following acute stroke therapy with IV-tPA. This underscores the risk of intraocular hemorrhage in patients with retinal neovascularization that could occur with other retinal vascular disorders such as diabetic retinopathy. The decision to proceed with IV-tPA in the presence of retinal neovascularization should be made on a case-by-case basis and further discussion with the patient.Disclosure: Dr. Shah has nothing to disclose. Dr. Verstraeten has nothing to disclose. Dr. Wright has nothing to disclose. Dr. Rana has nothing to disclose.
Source: Neurology - April 9, 2014 Category: Neurology Authors: Shah, L., Verstraeten, T., Wright, D., Rana, S. Tags: Cerebrovascular Disease and Interventional Neurology: Acute Stroke Thrombolysis Source Type: research

The quest to prevent stroke in atrial fibrillation: Fighting the fluttering heart in Singapore
There has been resurgence in the attention placed on pharmacotherapy in atrial fibrillation (AF) recently as specialists in international conferences discuss the utility of novel anticoagulants with caution owing to limited knowledge of the side effect profile in this nascent stage. AF is a well-known risk factor for stroke and has been for more than 20 years, since warfarin was demonstrated to reduce the risk of stroke, with aspirin doing so to a lesser degree.1 Today, there is international variation in the use of warfarin to prevent stroke despite well-established data.2 Singapore finds itself in a peculiar geographical...
Source: Neurology - June 2, 2014 Category: Neurology Authors: Goh, O., Lai, G., Tu, T. M., Lee, K. E. Tags: Cost effectiveness/economic, Stroke prevention, All Cerebrovascular disease/Stroke, Health care reform, Risk factors in epidemiology GLOBAL PERSPECTIVES Source Type: research

Ischemic Stroke in Patients with Elevated Body Mass Index while on Novel Anticoagulants: A case series report (P1.059)
CONCLUSIONS:We report and characterize the largest published case series of patients with non-valvular atrial fibrillation who had ischemic stroke while on novel oral anticoagulants. Elevated body mass index was noted among those who developed embolic strokes while on these agents.Disclosure: Dr. Kamal has nothing to disclose. Dr. Smith has nothing to disclose. Dr. Mowla has nothing to disclose. Dr. Shirani has nothing to disclose. Dr. Sawyer has nothing to disclose. Dr. Fanous has nothing to disclose. Dr. Ching has nothing to disclose.
Source: Neurology - April 8, 2015 Category: Neurology Authors: Kamal, H., Smith, K., Mowla, A., Shirani, P., Sawyer Jr., R., Fanous, A., Ching, M. Tags: Cerebrovascular Disease and Interventional Neurology: Atrial Fibrillation and Cardio-embolic Stroke Source Type: research

Acute ischemic stroke due to Left Ventricular Noncompaction Syndrome from a novel mutation of the Lamin A/C gene (P2.254)
Conclusion: LVNC is a risk factor for cardioembolic ischemic stroke particularly in young patients that is not well known. Patients with suspected LVNC by echocardiography should undergo cardiac MRI for confirmation and genetic testing in particular for mutations in the LMNA gene. The prognosis of those with LVNC syndrome is poor; most worsen over time and need ultimately transplantation. Close follow-up is required.Disclosure: Dr. Vongveeranonchai has nothing to disclose. Dr. Mittal has nothing to disclose. Dr. Ramos Estebanez has nothing to disclose. Dr. DeGeorgia has received personal compensation for activities with OS...
Source: Neurology - April 8, 2015 Category: Neurology Authors: Vongveeranonchai, N., Mittal, S., Ramos Estebanez, C., De Georgia, M. Tags: Cerebrovascular Disease and Interventional Neurology: Genetics and Stroke Source Type: research